SCHEMBL5228583

SCHEMBL5228583

COc1ccc2ccc3c(c2c1)C(=O)CCO3

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.44
MTNR1A P48039 2/20 0.42
NQO2 P16083 1/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
HNF4A P41235 1/20 0.40
MAPT P10636 4/20 0.40
LMNA P02545 1/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA3 P07451 1/20 0.39
AKR1B1 P15121 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769313 0.77 NPC1 (0.54) NPC1RAB9AMAPTKDM4EALDH1A1
SCHEMBL5223565 0.77 GAA (0.36) ALOX5MTNR1ANQO2HNF4AMAPT
SCHEMBL5223569 0.77 GAA (0.36) ALOX5MTNR1ANQO2HNF4AMAPT
SCHEMBL30873459 0.75 CYP19A1 (0.50) NPC1RAB9AMAPTLMNAKDM4E
SCHEMBL86076 0.75 CYP19A1 (0.50) NPC1RAB9AMAPTLMNAKDM4E
SCHEMBL67621 0.74 MAOB (0.60) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL19313470 0.74 MTNR1A (0.49) MTNR1A
Cyclopropane SCHEMBL28516873 0.73 MAOB (0.59) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL22135640 0.72 MTNR1A (0.48) MTNR1A
SCHEMBL5672208 0.72 HPGD (0.44) LMNAKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998471-B1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2007-03-14 EP disclosed
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 ALOX5 567/4885MTNR1A 1/4885NQO2 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.